Publication:

Angiotensin II drives the production of tumor-promoting macrophages

Loading...
Thumbnail Image

Date

2013

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Cortez-Retamozo, Virna, Martin Etzrodt, Andita Newton, Russell Ryan, Ferdinando Pucci, Selena W. Sio, Wilson Kuswanto, et al. 2013. “Angiotensin II Drives the Production of Tumor-Promoting Macrophages.” Immunity 38 (2): 296–308. https://doi.org/10.1016/j.immuni.2012.10.015.

Abstract

Macrophages frequently infiltrate tumors and can enhance cancer growth, yet the origins of the macrophage response are not well understood. Here we address molecular mechanisms of macrophage production in a conditional mouse model of lung adenocarcinoma. We report that overproduction of the peptide hormone Angiotensin II (AngII) in tumor-bearing mice amplifies self-renewing hematopoietic stem cells (HSCs) and macrophage progenitors. The process occurred in the spleen but not the bone marrow, and was independent of hemodynamic changes. The effects of AngII required direct hormone ligation on HSCs, depended on S1P(1) signaling, and allowed the extramedullary tissue to supply new tumor-associated macrophages throughout cancer progression. Conversely, blocking AngII production prevented cancer-induced HSC and macrophage progenitor amplification and thus restrained the macrophage response at its source. These findings indicate that AngII acts upstream of a potent macrophage amplification program and that tumors can remotely exploit the hormone's pathway to stimulate cancer-promoting immunity.

Description

Other Available Sources

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories